Colorectal Adenocarcinoma Clinical Trials in Los Angeles, California
8 recruitingLos Angeles, California
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
Alliance for Clinical Trials in Oncology364 enrolled185 locationsNCT05673148
Recruiting
Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Ewing SarcomaColorectal Adenocarcinoma
Inhibrx Biosciences, Inc411 enrolled36 locationsNCT03715933
Recruiting
Phase 1
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
Colorectal Adenocarcinoma
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT06225011
Recruiting
Phase 1
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal AdenocarcinomaRecurrent Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)30 enrolled15 locationsNCT06102902
Recruiting
Phase 1
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
University of Southern California15 enrolled3 locationsNCT06336902
Recruiting
Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793